[go: up one dir, main page]

BRPI0606191A2 - compostos de amino e carboxamido tetracìclicos e métodos do seu uso - Google Patents

compostos de amino e carboxamido tetracìclicos e métodos do seu uso

Info

Publication number
BRPI0606191A2
BRPI0606191A2 BRPI0606191-5A BRPI0606191A BRPI0606191A2 BR PI0606191 A2 BRPI0606191 A2 BR PI0606191A2 BR PI0606191 A BRPI0606191 A BR PI0606191A BR PI0606191 A2 BRPI0606191 A2 BR PI0606191A2
Authority
BR
Brazil
Prior art keywords
tetracyclic
methods
compound
amino
compounds
Prior art date
Application number
BRPI0606191-5A
Other languages
English (en)
Inventor
Prakash Jagtap
Csaba Szabo
Original Assignee
Inotek Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inotek Pharmaceuticals Corp filed Critical Inotek Pharmaceuticals Corp
Publication of BRPI0606191A2 publication Critical patent/BRPI0606191A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPOSTOS DE AMINO E CARBOXAMIDO TETRACìCLICOS E MéTODOS DO SEU USO. A presente invenção refere-se a compostos de amino tetracíclicos e compostos de carboxamido tetracíclicos, a composições compreendendo uma quantidade eficaz de um composto amino tetracíclico ou um composto carboxamido tetracíclico e a métodos para o tratamento ou prevenção de uma doença inflamatória, uma lesão por reperfusão, diabetes, uma complicação diabética, lesão por reoxigenação resultante de transplante de órgão, uma condição isquêmica, Doença de Parkinson, falha renal, uma doença vascular, uma doença cardiovascular, ou câncer, compreendendo administração a um indivíduo que necessita de uma quantidade eficaz de um composto amino tetracíclico ou um Tetraciclic Amino Compound ou composto carboxamido tetracíclico.
BRPI0606191-5A 2005-02-25 2006-02-15 compostos de amino e carboxamido tetracìclicos e métodos do seu uso BRPI0606191A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65663605P 2005-02-25 2005-02-25
PCT/US2006/005291 WO2006093667A1 (en) 2005-02-25 2006-02-15 Tetracyclic amino and carboxamido compounds and methods of use thereof

Publications (1)

Publication Number Publication Date
BRPI0606191A2 true BRPI0606191A2 (pt) 2009-06-09

Family

ID=36941478

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606191-5A BRPI0606191A2 (pt) 2005-02-25 2006-02-15 compostos de amino e carboxamido tetracìclicos e métodos do seu uso

Country Status (13)

Country Link
US (2) US7381722B2 (pt)
EP (1) EP1855676A4 (pt)
JP (1) JP2008531562A (pt)
KR (1) KR20070116011A (pt)
CN (1) CN101137377A (pt)
AU (1) AU2006219023A1 (pt)
BR (1) BRPI0606191A2 (pt)
CA (1) CA2598647A1 (pt)
IL (1) IL185259A0 (pt)
MX (1) MX2007010333A (pt)
RU (1) RU2007135362A (pt)
WO (1) WO2006093667A1 (pt)
ZA (1) ZA200707085B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030096833A1 (en) * 2001-08-31 2003-05-22 Jagtap Prakash G. Substituted ideno[1,2-c]isoquinoline derivatives and methods of use thereof
PL378331A1 (pl) * 2003-02-28 2006-03-20 Inotek Pharmaceuticals Corporation Tetracykliczne pochodne benzamidowe i sposoby ich stosowania
JP2007525526A (ja) * 2004-02-26 2007-09-06 イノテック ファーマシューティカルズ コーポレイション 四環系ラクタム誘導体およびその使用
MXPA06009701A (es) * 2004-02-26 2007-03-26 Inotek Pharmaceuticals Corp Derivados de isoquinolina y metodos de uso de los mismos.
CA2571001A1 (en) * 2004-06-16 2006-01-26 Inotek Pharmaceuticals Corporation Methods for treating or preventing erectile dysfunction or urinary incontinence
AU2006219022A1 (en) * 2005-02-25 2006-09-08 Inotek Pharmaceuticals Corporation Isoqunoline Compounds and methods of use thereof
EP1855676A4 (en) * 2005-02-25 2008-05-21 Inotek Pharmaceuticals Corp TETRAZYCLIC AMINO AND CARBOXAMIDE COMPOUNDS AND METHOD FOR THEIR USE
JP2008531563A (ja) * 2005-02-25 2008-08-14 イノテック ファーマシューティカルズ コーポレイション 四環スルホンアミド化合物およびこれらの使用法
CN101316592A (zh) * 2005-08-24 2008-12-03 伊诺泰克制药公司 茚并异喹啉酮类似物及其用法
US20100121049A1 (en) * 2007-02-28 2010-05-13 Inotek Pharmaceuticals Corporation Indenoisoquinolinone analogs and methods of use thereof
US12410185B2 (en) 2018-10-23 2025-09-09 Myelopro Diagnostics And Research Gmbh Compounds targeting mutant calreticulin

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
IT1054655B (it) 1975-08-27 1981-11-30 Lepetit Spa Derivati condensati del l isochinolina
US4263304A (en) 1978-06-05 1981-04-21 Sumitomo Chemical Company, Limited 7 H-indolo[2,3-c]isoquinolines
GB2025932B (en) 1978-06-13 1982-10-27 Sumitomo Chemical Co Indoloisoquinolines and processes for producing them
US5177075A (en) 1988-08-19 1993-01-05 Warner-Lambert Company Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
GB8828806D0 (en) 1988-12-09 1989-01-18 Beecham Group Plc Novel compounds
JP2845622B2 (ja) 1989-09-19 1999-01-13 マキシム ファーマシューティカルス，インコーポレイテッド インターロイキン―２とヒスタミン、その類似体又はｈ▲下２▼―受容体アゴニストを含む抗腫瘍性製剤
US5260316A (en) 1991-07-30 1993-11-09 Ciba-Geigy Corporation Isoquinolyl substituted hydroxylamine derivatives
US5597831A (en) 1991-08-29 1997-01-28 Vufb A.S 6-[X-(2-hydroxyethyl) aminoalkyl]-5,11-dioxo-5,6-dihydro-11-H-indeno[1,2-c]isoquinolines and their use as antineoplastic agents
SK278794B6 (sk) 1991-08-29 1998-03-04 V�Fb 2-hydroxyetylaminosubstituované deriváty 5,11-diox
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
TW440562B (en) 1994-05-20 2001-06-16 Taiho Pharmaceutical Co Ltd Condensed-indan derivative and pharmaceutically acceptable salts thereof
AU8784698A (en) 1997-08-15 1999-03-08 Johns Hopkins University, The Method of using selective parp inhibitors to prevent or treat neurotoxicity
US6250301B1 (en) 1997-08-28 2001-06-26 Hortal Harm B.V. Vaporizer for inhalation and method for extraction of active ingredients from a crude natural product or other matrix
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
AU9298198A (en) 1997-09-03 1999-03-22 Guilford Pharmaceuticals Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US6346536B1 (en) 1997-09-03 2002-02-12 Guilford Pharmaceuticals Inc. Poly(ADP-ribose) polymerase inhibitors and method for treating neural or cardiovascular tissue damage using the same
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US20020028813A1 (en) 1997-09-03 2002-03-07 Paul F. Jackson Thioalkyl compounds, methods, and compositions for inhibiting parp activity
CA2332239A1 (en) 1998-05-15 1999-11-25 Guilford Pharmaceuticals Inc. Fused tricyclic compounds which inhibit parp activity
JP2002515488A (ja) 1998-05-15 2002-05-28 ギルフォード ファーマシューティカルズ インコーポレイテッド カルボキサミド化合物、組成物、及びｐａｒｐ活性の抑制方法
KR20010072957A (ko) 1998-08-24 2001-07-31 추후보정 Ｈ2 수용체 작용제 및 기타 ｔ-세포 활성화제를 사용한ｔ-세포(ｃｄ4+ 및 ｃｄ8+) 활성화 및 보호 방법
AU765135B2 (en) 1998-10-14 2003-09-11 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Novel indenoisoquinolines as antineoplastic agents
JP2002528531A (ja) 1998-11-03 2002-09-03 ビーエーエスエフ アクチェンゲゼルシャフト 置換２−フェニルベンズイミダゾール、その製造法および使用
US6387902B1 (en) 1998-12-31 2002-05-14 Guilford Pharmaceuticals, Inc. Phenazine compounds, methods and pharmaceutical compositions for inhibiting PARP
US6201020B1 (en) 1998-12-31 2001-03-13 Guilford Pharmaceuticals, Inc. Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp
WO2000042040A1 (en) 1999-01-11 2000-07-20 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(adp-ribose) polymerases
US6346535B1 (en) 1999-01-29 2002-02-12 American Cyanamid Company Fungicidal mixtures
AU779215B2 (en) 1999-07-16 2005-01-13 Maxim Pharmaceuticals, Inc. Activation and protection of cytotoxic lymphocytes using a reactive oxygen metabolite inhibitor
US6465448B1 (en) 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
US6277990B1 (en) 1999-12-07 2001-08-21 Inotek Corporation Substituted phenanthridinones and methods of use thereof
GB0017508D0 (en) 2000-07-17 2000-08-30 Novartis Ag Antimicrobials
AUPR201600A0 (en) 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
US20030096833A1 (en) 2001-08-31 2003-05-22 Jagtap Prakash G. Substituted ideno[1,2-c]isoquinoline derivatives and methods of use thereof
US6956035B2 (en) 2001-08-31 2005-10-18 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
JP2003267888A (ja) 2002-03-15 2003-09-25 Seishi Yoneda 心停止液
US6992088B2 (en) 2002-08-09 2006-01-31 Rutgers, The State University Of New Jersey Nitro and amino substituted heterocycles as topoisomerase I targeting agents
EP1582520A1 (en) 2002-11-12 2005-10-05 Mochida Pharmaceutical Co., Ltd. Novel parp inhibitors
PL378331A1 (pl) * 2003-02-28 2006-03-20 Inotek Pharmaceuticals Corporation Tetracykliczne pochodne benzamidowe i sposoby ich stosowania
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
NZ547984A (en) 2003-12-01 2009-03-31 Kudos Pharm Ltd DNA damage repair inhibitors for treatment of cancer
MXPA06009701A (es) 2004-02-26 2007-03-26 Inotek Pharmaceuticals Corp Derivados de isoquinolina y metodos de uso de los mismos.
JP2007525526A (ja) 2004-02-26 2007-09-06 イノテック ファーマシューティカルズ コーポレイション 四環系ラクタム誘導体およびその使用
CA2571001A1 (en) 2004-06-16 2006-01-26 Inotek Pharmaceuticals Corporation Methods for treating or preventing erectile dysfunction or urinary incontinence
US20060079510A1 (en) 2004-09-30 2006-04-13 Kristoffer Hellstrand Use of PARP-1 inhibitors for protecting tumorcidal lymphocytes from apoptosis
AU2006219022A1 (en) 2005-02-25 2006-09-08 Inotek Pharmaceuticals Corporation Isoqunoline Compounds and methods of use thereof
EP1855676A4 (en) * 2005-02-25 2008-05-21 Inotek Pharmaceuticals Corp TETRAZYCLIC AMINO AND CARBOXAMIDE COMPOUNDS AND METHOD FOR THEIR USE
JP2008531563A (ja) 2005-02-25 2008-08-14 イノテック ファーマシューティカルズ コーポレイション 四環スルホンアミド化合物およびこれらの使用法
CN101316592A (zh) 2005-08-24 2008-12-03 伊诺泰克制药公司 茚并异喹啉酮类似物及其用法

Also Published As

Publication number Publication date
AU2006219023A1 (en) 2006-09-08
ZA200707085B (en) 2009-05-27
IL185259A0 (en) 2008-02-09
RU2007135362A (ru) 2009-03-27
US20060287312A1 (en) 2006-12-21
US7381722B2 (en) 2008-06-03
MX2007010333A (es) 2007-11-06
CN101137377A (zh) 2008-03-05
CA2598647A1 (en) 2006-09-08
JP2008531562A (ja) 2008-08-14
WO2006093667A1 (en) 2006-09-08
EP1855676A1 (en) 2007-11-21
US20080214593A1 (en) 2008-09-04
KR20070116011A (ko) 2007-12-06
EP1855676A4 (en) 2008-05-21

Similar Documents

Publication Publication Date Title
BRPI0508233A (pt) derivados de isoquinolina e métodos para emprego destes
BRPI0407757A (pt) derivados de benzamida tetracìclica e métodos de uso dos mesmos
BRPI0615096A2 (pt) análogos de indenoisoquinolinona e métodos de uso dos mesmos
NO20074737L (no) Isokinolinforbindelser og fremgangsmater for anvendelse derav
IL195030A (en) Dpp iv inhibitor formulations
BRPI0609393B8 (pt) usos de um composto 11-desóxi-prostaglandina
UY31296A1 (es) Composicion farmacéutica que comprende un derivado de benceno sustituido con glucopiranosilo
BRPI0611717A2 (pt) composto, composiÇço farmacÊutica e uso do composto
BRPI0606727A (pt) terapia de combinação para o tratamento de diabetes e condições relacionadas com ele e para o tratamento de condições melhoradas através de aumento no nìvel de glp-1 no sangue
BRPI0607240A2 (pt) derivados de maleimida, composições farmacêuticas e métodos para tratamento de cáncer
EA201300522A1 (ru) Фармацевтические комбинации для лечения метаболических нарушений
MX347525B (es) Inhibidores de tirosina cinasa de bruton.
EA201200968A1 (ru) Применение транс-кломифена для предотвращения или лечения диабета 2 типа у мужчин
EA200870472A1 (ru) Ингибиторы 11-бета-гидроксистероид-дегидрогеназы типа 1
WO2010029089A3 (en) Combination therapy for the treatment of diabetes and related conditions
EA200870475A1 (ru) Ингибиторы 11-бета-гидроксистероид-дегидрогеназы типа 1
ATE539079T1 (de) Imidazochinoxalinverbindungen als immunmodulatoren
BRPI0511703B8 (pt) composto, composição farmacêutica, e, métodos de tratar diabete melito tipo 2, de retardar o início do diabete melito tipo 2, de tratar hiperglicemia, diabete ou resistência à insulina, obesidade, síndrome x, um distúrbio lipídico, aterosclerose, e uma condição
MX2009002924A (es) Derivados de azetidinona espirociclica para el tratamiento de trastornos del metabolismo de los lipidos, el dolor, la diabetes y otros trastornos.
MY160703A (en) Crystalline forms of (r) -5- [3-chloro-4-(2,3-dihydroxy) - benz [z] ylidene] -2- ([z]-propylimino) -3-0-tolyl-thiazolidin-4-one
WO2007056681A3 (en) Methods for administering hypoglycemic agents
BRPI0923300A2 (pt) "derivados de nitrato de cilostazol para o tratamento de doenças vasculares e metabólicas"
BRPI0606191A2 (pt) compostos de amino e carboxamido tetracìclicos e métodos do seu uso
BRPI0509359A (pt) compostos de porfirina substituìda por piridila e métodos de empregos destes
BRPI0507189A (pt) uso combinado de um agonista de glp-1 e compostos de gastrina

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]